Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma
Language English Country United States Media print-electronic
Document type Journal Article
PubMed
28807336
DOI
10.1016/j.anndiagpath.2017.04.007
PII: S1092-9134(17)30088-6
Knihovny.cz E-resources
- Keywords
- Fumarate hydratase-deficient renal cell carcinoma, Kidney, PD-1 ligand (PD-L1) receptor, Programmed death-1 (PD-1) receptor,
- MeSH
- B7-H1 Antigen metabolism MeSH
- Programmed Cell Death 1 Receptor metabolism MeSH
- Adult MeSH
- Fumarate Hydratase deficiency metabolism MeSH
- Immunohistochemistry methods MeSH
- Carcinoma, Renal Cell metabolism pathology MeSH
- Middle Aged MeSH
- Humans MeSH
- Kidney Neoplasms metabolism pathology MeSH
- Disease-Free Survival MeSH
- Lymphocytes, Tumor-Infiltrating metabolism pathology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- B7-H1 Antigen MeSH
- Programmed Cell Death 1 Receptor MeSH
- CD274 protein, human MeSH Browser
- Fumarate Hydratase MeSH
- PDCD1 protein, human MeSH Browser
Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare and aggressive tumor affecting mostly younger patients. This is the first study to assess the expression of programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) in FH-RCC. Formalin-fixed paraffin-embedded samples from 13 FH-RCCs collected in an international multi-institutional study, were evaluated by immunohistochemistry (IHC) for PD-1/PD-L1 reactivity in tumor cells and tumor infiltrating lymphocytes (TILs). PD-1/PD-L1 expression was further evaluated by qPCR. By IHC, PD-1 was negative in tumor cells in all 13 cases. PD-L1 was positive in tumor cells in 2/13 cases, weak positive in 7/13, and negative in 4/13 cases, respectively. In TILs, PD-1 was positive in 1/13, weak positive in 3/13, and negative in 9/13 cases. In TILs, PD-L1 was weak positive by IHC in 5/13, and negative in 8/13 cases, respectively. qPCR confirmed the result for 2 of 3 IHC weak positive PD-1 samples. Of 7 IHC weak positive samples (in tumor cells), PD-L1 mRNA was detected in all 7 tumors. The majority of FH-RCCs did not express PD-1/PD-L1 by IHC, which was confirmed by molecular analysis. PD-1/PD-L1 expression in FH-RCC is restricted to a proportion of cases which may benefit from targeted therapies.
Bart's Cancer Center London United Kingdom
Calgary Laboratory Services University of Calgary Calgary AB Canada
Department of Pathology Bellvitge Biomedical Research Institute Barcelona Spain
Department of Pathology Instituto Nacional de Cancerologia Mexico City Mexico
Department of Pathology Medical College Wisconsin Milwaukee WI USA
Department of Pathology University Erlangen Germany
Robert J Tomsich Pathology and Laboratory Medicine Institute Cleveland Clinic Cleveland OH USA
References provided by Crossref.org
